| Autor: |
Kyoko, Nakamura, Masuho, Saburi, Yoshiyuki, Kondo, Yasuhiro, Soga, Kazuhito, Itani, Kazuhiro, Kohno, Makoto, Otsuka, Toshiyuki, Nakayama |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
[Rinsho ketsueki] The Japanese journal of clinical hematology. 60(12) |
| ISSN: |
0485-1439 |
| Popis: |
A 65-year-old man with multiple lymphadenopathy presented to our hospital and was diagnosed with StageIVA blastoid-variant mantle cell lymphoma (MCL), with a Ki-67 index of 93%. Partial response was achieved after four courses of CHASER (cyclophosphamide, cytarabine, dexamethasone, etoposide, and rituximab) chemotherapy, and complete response was achieved after autologous stem cell transplantation (ASCT). Six months after ASCT, the MCL relapsed with occurrence of tumors one on the left upper arm and one in the cerebrum, which were proved to be resistant to the conventional chemotherapy and progressed rapidly. These tumors disappeared with scarring following the local irradiation (45 Gy). However, the unirradiated regions became enlarged. The bulky abdominal lesion was treated with local irradiation (41 Gy) combined with 560 mg of ibrutinib but still resulted in progressive disease 1 month after initiating the ibrutinib treatment. Finally, the patient died 5 months post-relapse. The prognosis of patients with blastoid-variant MCL with high Ki-67 index is extremely poor. Furthermore, the risk of central nervous system (CNS) involvement is very high. Therefore, ibrutinib maintenance therapy post ASCT might be a treatment option to prevent CNS involvement. Further efforts might be needed to improve the outcomes of blastoid-variant MCL with a high Ki-67 index. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
